Shore Capital's recent research note on GSK PLC (LSE:GSK, NYSE:GSK) paints an optimistic picture for the pharmaceutical giant, underlining reasons for maintaining a 'Buy' recommendation with a raised fair value to 2,000p, up from 1,850p.
The note points out that GSK's current market valuation, trading at a price-to-earnings ratio (PER) of approximately nine times for the financial year 2025 (FY25F), is significantly lower than its peers, averaging around 15 times. This discrepancy is seen as largely unjustified, especially given GSK's promising growth trajectory.
Stifel has identified Novo Nordisk (NYSE:NVO), Merck KGaA and Sandoz as top picks in the European pharmaceutical sector for the first quarter of 2024, according to its recent research note.
Novo Nordisk (NYSE:NVO) is highlighted for its exceptional growth outlook, with analysts anticipating over 20% growth in 2024, distinct from its big pharma peers.
Analysts believe Fevertree Drinks (AIM:FEVR), the premium tonic company, is well-positioned to grow in the longer term, once the headwinds plaguing the industry begin to reduce.
Liberum experts raised the stock’s rating from ‘hold’ to ‘buy’ after noting that the stock is expected to recover ahead of consensus in 2025 and 2026.
Lloyds Banking Group PLC (LSE:LLOY) might be the worst affected of the major banks by the FCA’s clampdown on motor finance commissions, according to a couple of City firms.
Analysts at Barclays have analysed the comments from the regulator and believe that it raises the possibility of compensation being paid the banks.
Hercules Site Services' growth in 2023 was all organic says broker Cavendish and achieved across all the business areas (Labour Supply, Specialist Plant Services and Civil Projects).
Revenue growth should be strong in the current year as well, said the house, as labour shortages and significant planned spending in UK infrastructure boosts demand.
Porsche AG (ETR:P911) will likely report full-year earnings at the lower end of expectations after production bottlenecks hit deliveries of its Cayenne model, analysts say.
Revenue should sit at €41 billion (£35.2 billion) for the year, JP Morgan said in a note, with margins of 17.4% marking the low-end of the company’s 17% to 19% guided range.
IQGeo Group PLC (AIM:IQG)’s “remarkable” trading update posted on Monday, 15 January has caught the attention of analysts at house broker Cavendish, leading to sweeping earnings upgrades for the year ahead.
IQGeo's organic revenue growth stood at an impressive 56%, fuelling a 66% overall revenue growth, with the group’s 60% gross market reflecting “strong growth in recurring and services revenue”.
JP Morgan has maintained its bullish stance on AstraZeneca PLC (LSE:AZN) in the wake of the San Francisco healthcare conference it sponsors.
Repeating its overweight stance £130 a share price target, the US bank provided its assessment of a Q&A session fronted by AZ's CFO Aradhana Sarin, which presented a robust outlook for the company.
National Grid PLC (LSE:NG.) rose on Monday by 0.9% after Deutsche Bank upgraded its shares to ‘buy’ from ‘hold’.
The German investment bank noted throughout 2023, and for 20 months in total, it recommended investors position in integrated utilities.
Liberum, the boutique investment bank, has reiterated its 'buy' recommendation and 131p a share price target for Futura Medical PLC (AIM:FUM, OTC:FAMDF) after the sexual health products specialist announced that it had extended its licensing deal with Cooper Consumer Health for an additional two years.
This extension allows Cooper exclusive rights to commercialise Eroxon, Futura's erectile dysfunction (ED) gel, in the European Economic Area (EEA), the United Kingdom and Switzerland until 2029.
Airbus Group (EPA:AIR) will likely beat full-year earnings and free cash flow guidance after reporting higher-than-expected deliveries for 2023 last week, analysts have said.
France-based Airbus announced last week that it had delivered 735 aircraft over the year to December, marking an 11% increase on 2022.
Shares of Jadestone Energy PLC (AIM:JSE), the mid-cap oiler, were off 13% in early trade after it revealed the expenditure associated with two key fields would be higher than anticipated.
Specifically, operating costs for its Montara and Stag assets would be around US$95 million and US$65 million respectively. Peel Hunt, for example, had previously been estimating totals of US$65 million and US$40 million.